Xilio starts Phase 2 XTX301 (IL-12), gets $17.5M milestone from Gilead; cash extended to Q1 2027

Xilio Therapeutics, Inc.

Initiated patient dosing in Phase 2 of efarindodekin alfa (XTX301) for advanced solid tumors; RP2D selected.
Achieved $17.5M development milestone under Gilead license agreement; expects payment in Q4 2025.
As of June 30, 2025, cash and equivalents $121.6M; plus milestone extends cash runway into Q1 2027.
Phase 1 data: two partial responses (1 confirmed, 1 unconfirmed) in late-line advanced solid tumors; generally well-tolerated.
Gilead can elect to transition development after specified clinical data package for a $75M fee; Xilio eligible for up to $500M in milestones plus royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.